Kenneth Frazier, Merck & Co.

Chairman and CEO, Merck & Co.
Total 2014 Compensation:
$25.03 million

Merck & Co. ($MRK) had a good year in 2014, and that means Ken Frazier had a good year, too.

On the M&A side, he successfully sold off Merck's consumer health business for $14 billion to Bayer, part of a plan to focus the company on its strengths. He pushed through a $9.5 billion buyout of Cubist, the antibiotic specialist, in a move to build up Merck's hospital business. And he wrapped up a hepatitis C-focused deal for Idenix Pharmaceuticals, a $3.8 billion buy.

Plus, Frazier and his R&D team celebrated the approval of Keytruda, their cancer immunotherapy. It's widely expected to be a major blockbuster, not just in melanoma--where it was first approved--but in lung cancer and beyond. A hepatitis C cocktail is expected to follow it to market later this year.

Put those things together with a $2.5 billion cost-cutting plan and some stock gains, and you have a goal-beating year for Merck, which landed Frazier a $13 million-plus share grant. Frazier tacked on another $3.3 million in options, plus $3.34 million in cash incentive pay, thanks to goal-beating sales, earnings and pipeline milestones.

Frazier's base pay remained at $1.5 million. That figure, plus a $3.6 million increase in pension and deferred compensation, made up the rest of his 2014 total.

For more:
Special Reports: Top 15 pharma companies by 2014 revenue - Merck | 15 Highest-Paid Biopharma CEOs of 2013 - Kenneth Frazier - Merck
Merck cancer drugs and Sanofi, Amgen cardio meds have formularies on high alert
Report: Novo, Sanofi and Merck dominate global diabetes market
Merck's best hep C strategy is niche marketing, game theory expert figures
Merck's Frazier joins top-paid pharma CEOs with a $25M package
Merck CEO Frazier credits Keytruda success to slim-down strategy
Merck adds heft to hospital biz with $9.5B Cubist buyout

Kenneth Frazier, Merck & Co.
Read more on

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.